These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 23084910)

  • 1. A Blueprint for HIV Vaccine Discovery.
    Burton DR; Ahmed R; Barouch DH; Butera ST; Crotty S; Godzik A; Kaufmann DE; McElrath MJ; Nussenzweig MC; Pulendran B; Scanlan CN; Schief WR; Silvestri G; Streeck H; Walker BD; Walker LM; Ward AB; Wilson IA; Wyatt R
    Cell Host Microbe; 2012 Oct; 12(4):396-407. PubMed ID: 23084910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in HIV-1 vaccine development.
    Haynes BF; Moody MA; Alam M; Bonsignori M; Verkoczy L; Ferrari G; Gao F; Tomaras GD; Liao HX; Kelsoe G
    J Allergy Clin Immunol; 2014 Jul; 134(1):3-10; quiz 11. PubMed ID: 25117798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for a multi-stage neutralizing antibody-based HIV vaccine.
    Andrabi R; Bhiman JN; Burton DR
    Curr Opin Immunol; 2018 Aug; 53():143-151. PubMed ID: 29775847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response.
    Ahlers JD
    Discov Med; 2014 Apr; 17(94):187-99. PubMed ID: 24759623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
    Ahmad M; Ahmed OM; Schnepp B; Johnson PR
    Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural infection as a blueprint for rational HIV vaccine design.
    van Haaren MM; van den Kerkhof TL; van Gils MJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):229-236. PubMed ID: 27649455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
    Ahmed Y; Tian M; Gao Y
    AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
    Sliepen K; Sanders RW
    Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the N332-supersite of the HIV-1 envelope for vaccine design.
    Moyo T; Kitchin D; Moore PL
    Expert Opin Ther Targets; 2020 Jun; 24(6):499-509. PubMed ID: 32340497
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to HIV vaccine development.
    Haynes BF
    Curr Opin Immunol; 2015 Aug; 35():39-47. PubMed ID: 26056742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to the induction of HIV broadly neutralizing antibodies.
    Moore PL; Williamson C
    Curr Opin HIV AIDS; 2016 Nov; 11(6):569-575. PubMed ID: 27559709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.
    Liu CC; Zheng XJ; Ye XS
    ChemMedChem; 2016 Feb; 11(4):357-62. PubMed ID: 26762799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
    Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
    Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Alt FW; Tian M
    Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth.
    van Schooten J; van Gils MJ
    Retrovirology; 2018 Nov; 15(1):74. PubMed ID: 30477581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.